ISIN | IE00B28YJN35 |
---|---|
Valor Number | 3619126 |
Bloomberg Global ID | BBG000C22XY9 |
Fund Name | Polar Healthcare (USD Class) (USD Class) |
Fund Provider |
POLAR CAPITAL FUNDS PLC
London, United Kingdom Phone: +44 20 7227 2700 Web: www.polarcapital.co.uk |
Fund Provider | POLAR CAPITAL FUNDS PLC |
Representative in Switzerland | |
Distributor(s) |
AIG Privat Bank AG Zürich Phone: +41 44 227 55 55 |
Asset Class | Other Funds |
EFC Category | |
Distribution Policy | Other |
Home Country | Ireland |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies. The Fund will at all times invest at least two thirds of its total assets (excluding cash) in healthcare-related companies worldwide. The Fund will invest at least 51% of its gross assets on a continuous basis directly in Equity Participations. Subject to the investment restrictions described in Appendix II of the Prospectus, investments will be made in transferable securities including, but not limited to, shares, equity warrants and other types of securities such as preferred shares, which may be listed on a Regulated Market or unlisted, and issued by companies, and Global, American and European depository receipts. The Fund may not invest more than 10% of its Net Asset Value in unlisted securities. |
Peculiarities |
Current Price * | 54.07 USD | 02.10.2024 |
---|---|---|
Previous Price * | 54.66 USD | 01.10.2024 |
52 Week High * | 56.71 USD | 16.09.2024 |
52 Week Low * | 38.31 USD | 26.10.2023 |
NAV * | 54.07 USD | 02.10.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 2,028,435,198 | |
Unit/Share Assets *** | 19,637,062 | |
Trading Information SIX |
YTD Performance | +17.47% |
29.12.2023 - 02.10.2024
29.12.2023 02.10.2024 |
---|---|---|
YTD Performance (in CHF) | +18.60% |
29.12.2023 - 02.10.2024
29.12.2023 02.10.2024 |
1 month | -2.54% |
03.09.2024 - 02.10.2024
03.09.2024 02.10.2024 |
3 months | +6.48% |
02.07.2024 - 02.10.2024
02.07.2024 02.10.2024 |
6 months | +8.55% |
02.04.2024 - 02.10.2024
02.04.2024 02.10.2024 |
1 year | +33.24% |
02.10.2023 - 02.10.2024
02.10.2023 02.10.2024 |
2 years | +33.54% |
04.10.2022 - 02.10.2024
04.10.2022 02.10.2024 |
3 years | +18.34% |
04.10.2021 - 02.10.2024
04.10.2021 02.10.2024 |
5 years | +78.80% |
02.10.2019 - 02.10.2024
02.10.2019 02.10.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Swedish Orphan Biovitrum AB | 9.36% | |
---|---|---|
Zealand Pharma A/S | 8.34% | |
Novo Nordisk A/S Class B | 7.56% | |
UCB SA | 5.77% | |
Sanofi SA | 4.33% | |
argenx SE | 4.08% | |
Fresenius SE & Co KGaA | 4.05% | |
Intuitive Surgical Inc | 3.70% | |
Sandoz Group AG Registered Shares | 3.49% | |
Cytokinetics Inc | 3.15% | |
Last data update | 31.08.2024 |
TER *** | 1.18% |
---|---|
TER date *** | 31.12.2023 |
Performance Fee *** | 10.00% |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.63% |
SRRI ***
|
|
SRRI date *** | 30.09.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |